Angiotensin converting enzyme insertion/deletion (I/D) (rs4646994) and Vegf polymorphism (+405G/C; Rs2010963) in type II diabetic patients: Association with the risk of coronary artery disease

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 3, 2015, Pages 672-680

  Moradzadegan, Atousa ^a   Vaisi Raygani, Asad ^b   Nikzamir, Abdolrahim ^c   Rahimi, Zohreh ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiotensin converting enzyme (rs4646994); coronary artery disease; diabetes mellitus; genetic polymorphism; vascular endothelial growth factor (rs2010963)

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; VASCULOTROPIN; ACE PROTEIN, HUMAN; VASCULOTROPIN A;

ADULT; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIPEPTIDYL CARBOXYPEPTIDASE GENE; DISEASE PREDISPOSITION; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULOTROPIN GENE; COMPLICATION; DEMOGRAPHY; ENZYMOLOGY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; ODDS RATIO;

ALLELES; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDEL MUTATION; MALE; MIDDLE AGED; ODDS RATIO; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84950313086     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313497819     Document Type: Article

References (61)

1. Movva S, Alluri RV, Komandur S, et al. Relationship of angiotensin-converting enzyme gene polymorphism with nephropathy associated with type 2 diabetes mellitus in Asian Indians. J Diabetes Complications 2007; 21: 237-241.
2. Rahimi Z, Felehgari V, Rahimi M, et al. The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria. Mol Biol Rep 2010; 38: 2117-2123.
3. Hatmi ZN, Tahvildari S, Gafarzadeh Motlag A, et al. Prevalence of coronary artery disease risk factors in Iran: A population based survey. Cardiovasc Disord 2007; 7: 32: 1-5.
4. Arnett DK, Baird AE, Barkley RA, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: A scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007; 115: 2878-2901.
5. Kitsios G, Zintzaras E., ACE (I/D) polymorphism and response to treatment in coronary artery disease: A comprehensive database and meta-analysis involving study quality evaluation. Med Genet 2009; 10: 50-66.
6. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-1219.
7. Arfa I, Abid A, Nouira S, et al. Lack of association between the angiotensin-converting enzyme gene (I/D) polymorphism and diabetic nephropathy in Tunisian type 2 diabetic patients. J Renin Angiotensin Aldosterone Syst 2008; 9: 32-36.
8. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene of angiotensin converting enzyme is a potent risk factor for myocardial infraction. Nature 1992; 359: 641-644.
9. Marian A, Yu Q, Workman R, et al. Angiotensin converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 1993; 342: 1085-1086.
10. Kario K, Kanai N, Saito K, et al. Ischemic stroke and the gene for angiotensin converting enzyme in Japanese hypertensives. Circulation 1996; 93: 1630-1633.
11. Keavney B, McKenzie C, Parish S, et al. Large scale test of hypothesized associations between the angiotensin converting enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. Lancet 2000; 355: 434-442.
12. Francois B, Bernard K,. Angiotensin converting enzyme insertion or deletion polymorphism and coronary restenosis: A meta-analysis of 16 studies. Brit Med J 2002; 325: 517-520.
13. Sobti RC, Maithil N, Thakur H, et al. Association of ACE and FACTOR VII gene variability with the risk of coronary heart disease in north Indian population. Mol Cell Biochem 2010; 341: 87-98.
14. Inoue M, Itoh H, Ueda M, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: Possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998; 98: 2108-2116.
15. Fleisch M, Billinger M, Eberli FR, et al. Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation 1999; 100: 1945-1950.
16. Howell WM, Ali S, Rose-Zerilli MJ, et al. VEGF polymorphisms and severity of atherosclerosis. J Med Genet 2005; 42: 485-490.
17. Berse B, Brown LF, van de, Water L, et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211-220.
18. Namiki A, Brogi E, Kearney M, et al. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 1995; 270: 31189-31195.
19. Ray D, Mishra M, Ralph S, et al. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 2004; 53: 861-864.
20. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
21. Watson CJ, Webb NJ, Bottomley MJ, et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in VEGF protein production. Cytokine 2000; 12: 1232-1235.
22. Tsurumi Y, Murohara T, Krasinski K, et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med 1997; 3: 879-886.
23. Van Belle E, Tio FO, Chen D, et al. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J Am Coll Cardiol 1997; 29: 1371-1379.
24. Renner W, Kotschan S, Hoffmann C, et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000; 37: 443-448.
25. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28: S37-S42.
26. Vaisi-Raygani A, Ghaneialvar H, Rahimi Z, et al. The angiotensin converting enzyme D allele is an independent risk factor for early onset coronary artery disease. Clini Biochem 2010; 43: 1189-1194.
27. Friedewald WT, Levy RI, Fredrickson DS,. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
28. Feghhi M, Nikzamir A, Esteghamati A, et al. Relationship of vascular endothelial growth factor (VEGF) +405 G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes. Trans/ Res 2011; 158: 85-91.
29. Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin 1 converting enzyme(ACE) gene controls plasma ACE level. Am J Hum Genet 1992; 51: 197-205.
30. Gentilini D, Somigliana E, Vigano P, et al. The vascular endothelia growth factor 405G/C polymorphism in endometriosis. Hum Reprod 23: 211-215.
31. Vaisi-Raygani A, Zahrai M, Solt Anzadeh A, et al. (2004) Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease. Neurosci Lett 2008; 371: 142-146.
32. Wenquan N, Yue Q, Pingjin G, et al. Angiotensin converting enzyme D allele is associated with an increased risk of type 2 diabetes: Evidence from a meta-analysis. Endo cr J 2010; 57: 431-438.
33. Acartürk E, Attila G, Bozkurt A, et al. Insertion/deletion polymorphism of the angiotensin converting enzyme gene in coronary artery disease in Southern Turkey. J Biochem Mol Biol 2005; 38: 486-490.
34. Rodrigues GA, Matos BP, Fernandes de, Godoy M, et al. Homocysteine and MTHFR and VEGF gene polymorphisms: Impact on coronary artery disease. SBC 2009; 4: 249-254
35. Lin T-H, Wang C-L, Su H-M, et al. Functional vascular endothelial growth factor gene polymorphisms and diabetes: Effect on coronary collaterals in patients with significant coronary artery disease. Clin Chim Acta 2010; 411: 1688-1693.
36. Arbustini E, Grasso M, Fasani R, et al. Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. Br Heart J 1995; 74: 584-591.
37. Dzimiri N, Basco C, Moorji A, et al. Angiotensin-converting enzyme polymorphism and the risk of coronary heart disease in the Saudi male population. Arch Pathol Lab Med 2000; 124: 531-534.
38. Zintzaras E, Raman G, Kitsios G, et al. Angiotensin-converting enzyme insertion/deletion gene polymorphic variant as a marker of coronary artery disease: A meta-analysis. Arch Intern Med 2008; 168: 1077-1089.
39. Shafiee SM, Firoozrai M, Salimi S, et al. Angiotensin converting enzyme DD genotype not associated with increased risk of coronary artery disease in the Iranian population. Pathophysiology 2010; 17: 163-167.
40. Purnamasari D, Widjojo B, Antono D, et al. ACE Gene polymorphism and atherosclerotic lesion of carotid artery among off springs of type 2 diabetes mellitus. Acta Medica Indonesiana 2012; 44: 128-134.
41. Mannami T, Katsuya T, Baba S, et al. Low potentiality of angiotensin-converting enzyme gene insertion/deletion polymorphism as a useful predictive marker for carotid atherogenesis in a large general population of a Japanese city: The Suita study. Stroke 2001; 32: 1250-1256.
42. Samani NJ, Thompson JR, O'Toole L, et al. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 1996; 94: 708-712.
43. Tiret L, Bonnardeaux A,. Synergistic effects of angiotensin-converting enzyme and angiotensin II type 1 receptor DD genotype of the gene polymorphisms on risk of myocardial infarction. Lancet 1994; 344: 910-913.
44. Jeunemaitre X, Ledru F, Battaglia S,. Genetic polymorphisms of the reninangiotensin system and angiographic extent and severity of coronary artery disease: The CORGENE study. Hum Genet 1997; 99: 66-73.
45. Yang Q, Khoury MJ,. Evolving methods in genetic epidemiology III. Gene environment interaction in epidemiologic research. Epidemiol Rev 1997; 19: 33-43.
46. Grosskrutz CL, Anand-Apte B, Duplaa C, et al. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res 1999; 58: 128-136.
47. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425-429.
48. Van der Mreer P, De Boer RA, White HL, et al. The VEGF -405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: A MERIT-HF Substudy. J Card Fail 2005; 11: 279-284.
49. Matos BP, Rodrigues GA, Fernandes de, Godoy M, et al. Vascular endothelial growth factor genetic variability and coronary artery disease in Brazilian population. Heart Vessels 2008; 23: 371-375.
50. Srivatsa SS, Edwards WD, Boos CM, et al. Histologic correlates of angiographic chronic total coronary artery occlusions. J Am Coll Cardiol 1997; 29: 955-963.
51. Moulton KS, Vakili K, Zurakowski D, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003; 100: 4736-4741.
52. Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-2767.
53. Ohishi M, Ueda M, Rakugi H, et al. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 1997; 15: 1295-1302.
54. Chobanian AC, Haudenschild C, Nickerson C, et al. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15: 327-331.
55. Dahlo FB, Pennert K, Hansson L,. Reversal of left ventricular hypertrophy in hypertensive patients-a metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
56. Pastuszczak M, Branicka A, Jakiela B, et al. The +405 GG variant of vascular endothelial growth factor polymorphism is associated with poor prognosis in patients undergoing coronary artery bypass graft surgery. Pol Arch Med Wewn 2009; 119: 719-725.
57. Couffinhal T, Kearney M, Witzenbichler B, et al. Vascular endothelial growth factor/vascular permeability factor (VEGF/ VPF) in normal and atherosclerotic human arteries. Am J Pathol 1997; 150: 1673-1685.
58. Ruef J, Hu ZY, Yin LY, et al. Induction of vascular endothelial growth factor in balloon-injured baboon arteries. A novel role for reactive oxygen species in atherosclerosis. Circ Res 1997; 81: 24-33.
59. Petrovic D, Verhovec R, Globocnik PM, et al. Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology 2007; 107: 291-295.
60. Saijonmaa O, Nyman T, Kosonen R, et al. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am J Physiol Heart Circ Physiol 2001; 280: H885-H891.
61. Saijonmaa O, Nyman T, Stewen P, et al. Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. Am J Physiol Heart Circ Physiol 2004; 286: H2096-H2102.